日本临床早期声门型喉癌的放化疗综合治疗：10 个机构分析。
Combined chemoradiotherapy for early glottic cancer in clinical practice in Japan: analysis of 10 institutions.
机构信息
Department of Radiology, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8560, Japan.
出版信息
Anticancer Res. 2010 Dec;30(12):5181-4.
AIM
To conduct a retrospective analysis regarding treatment strategies for early glottic cancer (GC) at ten institutions.
PATIENTS AND METHODS
A questionnaire-based survey was used to obtain personal and medical information on patients who started radiation therapy for T1 or T2 GC between January 2000 and December 2005.
RESULTS
A total of 279 patients were registered for the survey, of whom 124 patients were classified as T1a, with 65 patients as T1b and 87 patients as T2. The rates of chemoradiotherapy for T1a, T1b and T2 were 24%, 23% and 60%, respectively. A comparison of results for academic and non-academic hospitals showed statistically different rates of combination therapy for T1a (6.9% vs. 39.3%, respectively; p<0.001) and T1b (11.4% vs. 36.6%, respectively; p<0.05) but not for T2 (70.0% vs. 54.4%, respectively; p = 0.158).
CONCLUSION
In clinical practice, combined chemoradiotherapy was performed for early GC at most institutions in Tokai District, Japan.
目的
对十家机构治疗早期声门癌（GC）的策略进行回顾性分析。
患者和方法
采用基于问卷调查的方式，收集 2000 年 1 月至 2005 年 12 月期间开始接受 T1 或 T2 GC 放射治疗的患者的个人和医疗信息。
结果
共有 279 名患者注册参与调查，其中 124 名患者被分类为 T1a，65 名患者为 T1b，87 名患者为 T2。T1a、T1b 和 T2 患者接受放化疗的比例分别为 24%、23%和 60%。学术医院和非学术医院的结果比较显示，T1a（6.9%比 39.3%；p<0.001）和 T1b（11.4%比 36.6%；p<0.05）的联合治疗率存在统计学差异，但 T2 无差异（70.0%比 54.4%；p = 0.158）。
结论
在日本东海地区，大多数机构在临床实践中对早期 GC 采用了放化疗联合治疗。
Zotero 插件